Evidence map›Paper›PMID 42781313›Full record

ArticleBio-protocol2026

Protecting Against Cytoplasmic Protein Aggregates With Cytoplasmic PML Variants.

Jia-Xin Zhu, Yuchen Xia, Jiaqi Liu, Li Cao, Steven X Hou, Yang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia-Xin ZhuState Key Laboratory of Genetic Engineering, Department of Cell and Developmental Biology at School of Life Sciences, Fudan University, Shanghai, China.
Yuchen XiaState Key Laboratory of Genetic Engineering, Department of Cell and Developmental Biology at School of Life Sciences, Fudan University, Shanghai, China.
Jiaqi LiuState Key Laboratory of Genetic Engineering, Department of Cell and Developmental Biology at School of Life Sciences, Fudan University, Shanghai, China.
Li CaoDepartment of Neurology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Steven X HouState Key Laboratory of Genetic Engineering, Department of Cell and Developmental Biology at School of Life Sciences, Fudan University, Shanghai, China.
Yang WangState Key Laboratory of Genetic Engineering, Department of Cell and Developmental Biology at School of Life Sciences, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytoplasmic protein aggregation is a defining feature of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, and certain forms of motor neuron disease. Recent evidence indicates that promyelocytic leukemia protein (PML) and engineered PML-derived variants can act as versatile aggregate-remodeling factors. In particular, cytoplasmically redirected PML variants recognize pathological cytoplasmic inclusions and promote their clearance. Here, we describe a protocol to generate and validate two engineered cytoplasmic PML variants: full-length mPML, which is redirected to the cytoplasm by disruption of its nuclear localization sequence, and the truncated mPML

Indexed as

Aggregate clearanceCytoplasmic protein aggregatesNeurodegenerationPMLSOD1TDP-43

Identifiers

PMID42781313
PMCPMC13598655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.